AUTL — Autolus Therapeutics plc Stock Price, Chart & AI Report

Neutral Feb 24, 2026 • 12:00 UTC GlobeNewswire Inc. • Na

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics plc announced participation in two upcoming investor conferences in March 2026 (TD Cowen Health Care Conference on March 3 and Jefferies Biotech on the Beach Summit on March 10). The company also announced preliminary unaudited fourth quarter and full year 2025 net product revenue from AUCATZYL® sales, along with pipeline advancements and 2026 outlook.

AUTL Autolus Therapeutics T cell therapies AUCATZYL investor conference product revenue biopharmaceutical cancer treatment

Sentiment note

The article announces routine investor conference participation and preliminary financial results without providing specific revenue figures, growth metrics, or forward guidance details. While the company has a marketed therapy and pipeline advancement, the lack of concrete performance data and the preliminary nature of the announcement prevent a more definitive positive or negative assessment.

Positive Nov 25, 2025 • 09:00 UTC GlobeNewswire Inc. • Autolus Therapeutics Plc

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

The National Institute for Health and Care Excellence (NICE) has recommended AUCATZYL®, a CAR T cell therapy developed by Autolus Therapeutics, as a treatment option for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in England and Wales.

AUTL CAR T cell therapy leukemia NICE recommendation AUCATZYL B-cell ALL

Sentiment note

Company received NICE recommendation for its innovative CAR T cell therapy, indicating potential market expansion and clinical validation of its treatment

Positive Oct 27, 2025 • 11:00 UTC GlobeNewswire Inc. • Autolus Therapeutics

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

Autolus Therapeutics presented promising Phase 1 clinical trial data for obe-cel, a CAR T cell therapy targeting severe refractory systemic lupus erythematosus, showing high remission rates and potential for meaningful clinical impact.

AUTL CAR T cell therapy lupus clinical trial immunotherapy rheumatology

Sentiment note

Positive clinical trial results with 83% patient remission, no serious adverse events, and clear pathway to Phase 2 trial demonstrate promising therapeutic potential

Positive Oct 20, 2025 • 11:00 UTC GlobeNewswire Inc. • Autolus Therapeutics

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

Autolus Therapeutics initiated a Phase 1 clinical trial of obecabtagene autoleucel (obe-cel) for progressive multiple sclerosis, dosing the first patient at University College London Hospitals NHS Foundation Trust to evaluate the therapy's safety and potential efficacy.

AUTL multiple sclerosis CAR T cell therapy clinical trial progressive MS autoimmune disease

Sentiment note

Company is advancing innovative CAR T cell therapy into a new disease area with significant unmet medical need, demonstrating potential for expanding treatment options for progressive multiple sclerosis patients

Positive Aug 12, 2025 • 11:00 UTC GlobeNewswire Inc. • Autolus Therapeutics Plc

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Autolus Therapeutics reported Q2 2025 net product sales of $20.9 million for AUCATZYL®, received marketing authorization in the UK and EU, and presented long-term data from the FELIX trial demonstrating potential for long-term remission in relapsed/refractory B-ALL.

AUTL CAR T cell therapy AUCATZYL B-cell acute lymphoblastic leukemia marketing authorization clinical trial

Sentiment note

Positive commercial progress with AUCATZYL® launch, regulatory approvals in UK and EU, promising clinical trial data, and ongoing development of obe-cel in multiple indications

Positive Jul 21, 2025 • 11:00 UTC GlobeNewswire Inc. • Autolus Therapeutics

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Autolus Therapeutics received European marketing authorization for AUCATZYL®, a CAR T cell therapy treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, based on successful FELIX clinical trial results.

AUTL CAR T therapy leukemia immunotherapy marketing authorization clinical trial

Sentiment note

Received European marketing authorization for AUCATZYL®, demonstrating successful clinical trial results and expanding market potential for their innovative CAR T cell therapy

Neutral Apr 22, 2025 • 11:00 UTC GlobeNewswire Inc. • N/A

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Autolus Therapeutics, an early commercial stage biopharmaceutical company, will release its first quarter 2025 financial results and host a conference call on May 8, 2025 to discuss the company's financial results and provide a general business update.

AUTL Autolus Therapeutics financial results conference call

Sentiment note

The article provides factual information about Autolus Therapeutics' upcoming financial results and conference call, without any explicit positive or negative sentiment.

Positive Apr 2, 2025 • 11:00 UTC GlobeNewswire Inc. • N/A

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Autolus Therapeutics, an early commercial-stage biopharmaceutical company, announces its participation in the 24th Annual Needham Virtual Healthcare Conference, where CEO Dr. Christian Itin will present in a Fireside Chat.

AUTL Autolus Therapeutics biopharmaceutical T cell therapies cancer autoimmune disease

Sentiment note

The article highlights Autolus Therapeutics as an early commercial-stage biopharmaceutical company developing next-generation T cell therapies for the treatment of cancer and autoimmune diseases. Its participation in a major industry conference and the presentation by the CEO suggest the company is actively engaged in advancing its pipeline and business.

Positive Mar 6, 2025 • 12:00 UTC GlobeNewswire Inc. • N/A

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Autolus Therapeutics, an early commercial stage biopharmaceutical company, will release its fourth quarter and full year 2024 financial results and operational highlights on March 20, 2025. The company will host a conference call and webcast to discuss the financial results and provide a business update.

AUTL Autolus Therapeutics financial results conference call biopharmaceutical company

Sentiment note

The article announces that Autolus Therapeutics will be reporting its financial results and hosting a conference call, which suggests the company is actively engaged in its business operations and providing updates to investors.

Positive Mar 5, 2025 • 18:00 UTC GlobeNewswire Inc. • Delveinsight

CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain

The CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.

RNAC ACLX AUTL SANA CAR T-cell therapy cancer treatment pipeline clinical trials

Sentiment note

The company is developing AUTO-8, a pipeline candidate for the treatment of multiple myeloma.

Positive Dec 10, 2024 • 00:30 UTC GlobeNewswire Inc. • Autolus Therapeutics Plc

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Autolus Therapeutics presented positive clinical data updates on their CAR-T therapy obe-cel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) at the ASH 2024 annual meeting. The data showed high rates of deep molecular remission, improved event-free and overall survival, and reduced healthcare resource utilization costs associated with managing side effects.

AUTL Autolus Therapeutics obe-cel CAR-T therapy relapsed/refractory B-cell acute lymphoblastic leukemia ASH 2024

Sentiment note

The article presents positive clinical data updates on Autolus Therapeutics' CAR-T therapy obe-cel, which showed high rates of deep molecular remission, improved outcomes, and reduced healthcare costs. This suggests the therapy is performing well in clinical trials and has the potential to be an effective treatment for r/r B-ALL.

Neutral Sep 2, 2024 • 11:00 UTC GlobeNewswire Inc. • N/A

Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today

Oxford Biomedica, a cell and gene therapy CDMO, has appointed Lucinda Crabtree as its new Chief Financial Officer. Crabtree brings extensive experience from her previous roles at MorphoSys, Autolus Therapeutics, and the investment and banking sectors.

AUTL GS GSPA GSPC Oxford Biomedica Lucinda Crabtree Chief Financial Officer cell and gene therapy

Sentiment note

The article states that Lucinda Crabtree was previously CFO at Autolus Therapeutics, a Nasdaq-listed clinical-stage biopharmaceutical company, but does not provide any further details, so a neutral sentiment is assigned.